Global Blood Therapeutics, Inc.

Roche Palo Alto LLC

F. Hoffmann-la Roche Ag

Calvin Wesley Yee

Zhe Li

Qing Xu

Brian Walter Metcalf

Stephen L Gwaltney, Ii

Jason R Harris

Hing L Sham

Lina Quattrocchio Setti

Ming Yu

Chul Yu

Peter Michael Rademacher

Carsten Alt

Yan Lou

Stephen L Gwaltney

Timothy D Owens

Rama K Kondru

Johannes Cornelius Hermann

Robert Than Hendricks

Manuel Zancanella

Daisy Joe DuBois

Shahul Nilar

David Bernard Smith

Michael Soth

Todd Richard Elworthy

Hanbiao Yang

Daisy Joe Du Bois

Remy Lemoine

Joe Timothy Bamberg

Jaehyeon Park

Steven Richards

Matthew A Lardy

Mark Bartlett

Stephen L Ii Gwaltney

Ii Stephen L Gwaltney

The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I' and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

Cycloalkyl pyrimidines as ferroportin inhibitors

The present disclosure provides tricyclic compounds of formula (I) that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds. 

Tricyclic compounds as histone methyltransferase inhibitors

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

Compounds and uses thereof for the modulation of hemoglobin

The subject matter described herein is directed to Ferroportin inhibitor compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis. The compounds of Formula I and pharmaceutical salts thereof have the following structure: wherein R, R, R, X, X, X, X, Y, Y, and Yare as described herein.

Ferroportin inhibitors and methods of use

Provided herein are kallikrein modulating compounds, pharmaceutical compositions comprising the same, and uses thereof.

Bridged bicyclic kallikrein inhibitors

In one aspect this invention relates generally to compounds of Formula: and sub-formulas thereof, or a tautomer of each thereof, a pharmaceutically acceptable salt of each thereof, or a pharmaceutically acceptable solvate of each of the foregoing, where X, L, L, and Rare described herein.

Pyrazolopyridine pyrazolopyrimidine and related compounds

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q and R are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

Pyrrolopyrazine kinase inhibitors

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Qand R are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

Growing community of inventors

Daly City, CA, United States of America

Calvin Wesley Yee